Engineered exosomes that naturally go to brain and kidney cells can deliver gene‑silencing drugs far beyond the liver.

A nanobody that stabilizes mutant CFTR from inside the cell, especially when combined with existing drugs, restores near-normal function in cystic fibrosis cells.

Should Medicare change the default option for new beneficiaries to Medicare Advantage or an ACO, this could backfire as costs could rise and access restrictions increase.

In Congress, hearings on healthcare tend to function as venues for adversarial political messaging and electoral gain rather than legislative consensus-building.

White House model estimates on cost savings from most-favored nation drug prices are speculative and depend on a set of unrealistic assumptions.

Those with a vested interest in the status quo, are resisting transparency regulations. After all, maintaining opaque pricing in healthcare has been profitable to them.

Despite more than two decades of safe and effective use, the abortion pill is once more in the crosshairs of American politics and the judicial system.

Policy experts suggest reform of prior authorization that would require coverage decisions be supported solely by evidence being reviewed by independent clinicians.

DTC portals for drugs are a solution to a problem that wouldn’t exist if insurer coverage were better. The most acute issue for patients is lack of comprehensive coverage

If increased transparency isn’t the answer, what could meaningfully lower patients’ out-of-pocket costs? Reduced prices of care throughout all of healthcare would help.